Mycoplasmal contamination of cell culture systems continues to present major problems for basic research and for manufacturing of bioproducts. Previous work suggested that certain antibiotics have strong anti-mycoplasma properties and raised the prospect that the technically rather simple antibiotic treatment may be an appropriate means for mycoplasma eradication. We have developed and validated an effective strategy to eliminate mycoplasma from chronically infected cell cultures using antibiotics which have shown strong activity against these contaminants. Here, we describe our experience with the treatment of 123 consecutive mycoplasma-positive leukemialymphoma cell lines, comparing five different antibiotic regimens (in total 433 treatments). We optimized the antibiotic dose schedules and the duration of treatments. The various antibiotic treatments which were employed in parallel had a high efficacy, as 71% to 86% of the infected cultures were cleansed. Treatment failure may result from the resistance of the mycoplasmas to antibiotic therapy and the inability of the eukaryotic cells to survive the cytotoxic effects of the antibiotics. Resistance to mycoplasma eradication was observed in 3% to 20% of the cultures. Loss of the cell culture caused by cytotoxicity was seen in 3% to 11% of the treatments. With regard to the overall outcome, 96% of the cell lines were rendered mycoplasma-free with at least one of the antibiotic treatments and were permanently cured. In conclusion, antibiotic treatment represents the most practical and efficient option to cleanse mycoplasma-positive cell lines.
Introduction
Since the first reports on mycoplasma contamination of cell cultures, attempts to develop methods for elimination of the mycoplasma have been made. It has been suggested that efforts to eradicate mycoplasmas from contaminated cells should be considered as a last resort (in order to prevent spread of the contaminant) and that it would be often far better to eliminate the problem completely by autoclaving the infected cultures and replacing them with fresh stocks known to be mycoplasma-free. 1 However, in some instances the cell line is not easily replaceable with a mycoplasma-free aliquot and purging of mycoplasmas directly from such cultures may be necessary. ate mycoplasmas from infected cell cultures: physical, chemical, immunological and chemotherapeutic (= antibiotic) treatment (Table 1) . Elimination is typically time-consuming, often unsuccessful and poses risks of secondary infection to other cell cultures. Methods of elimination should ideally be simple and easy, rapid and efficient, reliable and inexpensive, have minimal effect on the eukaryotic cell and result in no loss of specialized characteristics; accidental cloning selection of treated cells should also not occur. However, there is clearly not a single method available that is both 100% effective and fulfills all the ideal requirements. The physical, chemical and immunological methods are usually of restricted value since the mycoplasmas are commonly not entirely eliminated, but only suppressed (low efficiency). Some methods are time-consuming or have detrimental effects on the eukaryotic cells. Other techniques are complex or impractical as they require extensive resources or special equipment and knowledge (a detailed discussion of these methods has been presented in Ref. 2) .
Considering the various advantages and disadvantages of any elimination procedure, antibiotic intervention appears to be superior to the other mycoplasma eradication techniques and is thus the method of choice. The simple addition of Table 1 Various mycoplasma elimination methods another reagent to a cell culture is within the technical and financial possibilities of every cell culture laboratory. Mycoplasmas, which lack a cell wall and are incapable of peptidoglycan synthesis, are theoretically not susceptible to antibiotics such as penicillin and its analogues, which are effective against most bacterial contaminants of cell cultures. However, it has been reported that several bacteriostatic antimicrobial agents inhibit the growth of mycoplasmas. Thus, while not eradicating the contaminants, they may only suppress the full-blown picture of an infection, thereby masking the presence of mycoplasmas. A number of different antibiotics has been explicitly used for mycoplasma control. 2 The contaminant strains, however, often developed resistance to certain antibiotics which were thus completely ineffective. Several antibiotics were moderately to highly effective in eliminating mycoplasmas, but only at concentrations which had detrimental effects on the eukaryotic cells, such as marked cytotoxicity (presented in detail in Ref. 2) .
Physical procedures
Ideally, a basic procedure should involve isolating, speciating, and determining the antibiotic susceptibility of the contaminants to the arsenal of possible reagents to maximize success; then the cultures should be exposed to the effective antibiotics. However, this approach is extremely time-consuming, labor-intensive and requires certain expertise. A more simple and quick procedure would definitely be of advantage.
As pointed out elsewhere, 3 a large percentage of continuous cell lines is infected with mycoplasma, including leukemialymphoma (LL) cell lines. In a prospective study, we sought to develop and validate a procedure to cleanse these contaminated LL cell lines from the infectant as efficiently, quickly and simply as possible. To that end, we exposed the mycoplasmapositive cell cultures to various antibiotics which we feel is the most practical way to solve this problem. Pharmacological and clinical testing has shown that tetracyclines and quinolones are generally effective anti-mycoplasmal agents. Hence, we concentrated our efforts on the application of such mycoplasmacidal antibiotics for the purging of contaminated cell cultures.
Materials and methods

Cell lines
All mycoplasma-infected cell lines are continuous human LL cell lines growing in suspension. 4 Cultures were grown either in 24-well-plates or 50 ml plastic flasks (Nunc, Wiesbaden, Germany) in basic growth media (Gibco BRL Life Technologies, Karlsruhe, Germany) supplemented with 5-20% mycoplasma-free, heat-inactivated (at 56°C for 45 min) fetal bovine serum (FBS; Sigma, Deisenhofen, Germany) under standard culture conditions (37°C, 5% CO 2 , 90% humidity). No other supplements (including any antibiotics) were routinely added. None of the cell lines were deliberately infected with mycoplasmas, but rather represented chronically contaminated cultures. Cultures were passaged according to standard procedures and spent culture medium was exchanged at regular intervals (usually after 24-48 h).
Mycoplasma detection
The mycoplasma status was examined before and after antibiotic treatment with the following four detection methods which have been described in details elsewhere:
2,5-8 (1) cytoLeukemia chemical DNA fluorescence staining with DAPI (4′,6-diamidino-2-phenylindole; Sigma); (2) classical microbiological broth-agar colony assay; (3) molecular biological DNA-RNA hybridization assay (Gen-Probe; BioMérieux, Nü rtingen, Germany); and (4) polymerase chain reaction (PCR). Mycoplasma contamination was always assessed with three independent procedures: DAPI, Gen-Probe and agar were used from 1990 to 1997; PCR, Gen-Probe and agar were employed from 1998 to 2001.
Mycoplasma elimination
Cell culturing during anti-mycoplasma treatment: Spent medium of the LL cell line cultures was replaced with fresh medium containing the various antibiotics during the treatment period. Cultures were always thoroughly mixed in order to ensure optimal distribution of the reagents and access of the reagents to the mycoplasma cells commonly attached to the eukaryotic cell membrane. It is particularly important to break up clumps and clusters as these may represent sanctuaries for the infectants to which the antibiotics do not have physical access. During treatment, cultures were kept at high densities with a higher concentration of FBS than usually employed (+5-10% additional FBS) to counterbalance the possible toxic or growth-inhibiting effects of treatment by enhanced proliferation. Initially, cultures were treated in flasks in volumes of 10-20 ml. Later we used mainly 24-well plates with volumes of 1-2 ml per well. These plates are optimal for handling the cells (pipetting, splitting, etc) and for observing the cells under the inverted microscope. At the end of the treatment periods of 7-21 days, cells were washed twice and resuspended in fresh complete medium without any antimycoplasma or other antibiotics. Cells were then grown antibiotic-free for at least 2 weeks in order to enrich any residual mycoplasmas up to detectable levels or to get rid off residual mycoplasmal DNA. All cultures were examined with at least three of the above-mentioned detection assays. In most instances, cultures were reexamined again at later time points.
Treatment with BM-cyclin, ciprofloxacin, enrofloxacin, MRA, sparfloxacin:
The treatment protocols using BM-cyclin, ciprofloxacin, enrofloxacin, and mycoplasma removal agent (MRA) have been described in detail elsewhere. 5,9,10 A short summary is given in Table 2 . Treatment with BM-cyclin (Roche, Mannheim, Germany; Cat. No. 799050) included BM-cyclin I containing the macrolide tiamulin for 3 days followed by BM-cyclin II containing the tetracycline minocycline for 4 days. This alternating cycle was used three times. The final concentrations of BM-cyclin I and of BM-cyclin II were 10 g/ml (4 l/ml) and 5 g/ml (4 l/ml), respectively. Cells were exposed to the quinolone ciprofloxacin (Ciprobay 100; Bayer, Leverkusen, Germany) at 10 g/ml (= 5 l/ml) for 14 days. Cells were treated with the quinolone enrofloxacin (Baytril; Bayer) for 7 days; the original ready-to-use solution with a concentration of 100 mg/ml was diluted 1:100 with RPMI 1640 medium; 25 l of the latter solution were added for each milliliter of culture volume (final concentration of 25 g/ml). The quinolone MRA (ICN, Eschwege, Germany; Cat. No. 30-500-44 or as MC210, Cat. No. KE-M210 by Dainippon, Osaka, Japan) contains a 4-oxo-quinoline-3-carboxylic acid derivative and was added to cell cultures at 0.5 g/ml (= 10 l/ml). Cultures were treated for 7 days. Treatment with the quinolone sparfloxacin (Zagam, kindly pro- a Based on extensive experimental evaluation, 5,9,10 we recommend the indicated treatment periods and antibiotic concentrations. For BMcyclin and MRA, we followed the suppliers' recommendations. b Final concentrations of antibiotic per milliliter of cell culture. BM-cyclin and MRA are ready-to-use solutions which are specifically marketed for use as cell culture anti-mycoplasma antibiotics. Ciprobay 100 and Baytril are available as injection solutions (which are normally used in human medicine and veterinary medicine, respectively). Baytril needs to be diluted 1:100 with RPMI 1640 medium prior to use. All reagents appear to be light sensitive and, except for BM-cyclin which is stored frozen, should be kept light-protected at 4°C. BM-cyclin can be thawed and refrozen many times without any loss of efficacy. The Baytril and sparfloxacin solutions for use should be prepared freshly for each treatment from the stock solutions. c MRA (Mycoplasma Removal Agent) contains an undisclosed 4-oxo-quinoline-3-carboxylic acid derivative which is produced by Dainippon, Osaka, Japan.
vided as powder by Rhone-Poulenc, Vitry-sur-Seine, France) was performed for 7 days at 10 g/ml (= 1 l/ml of a 1:1 dilution of the stock solution in RPMI 1640 medium; stock solution: 20 mg/ml dissolved in 0.1 n NaOH).
Results
Mycoplasma-contaminated cell lines
In total, 123 mycoplasma-positive LL cell lines were treated with antibiotics. These cell lines were all chronically infected cultures and not experimentally, short-term contaminated cultures. This is of importance as there is a significant difference between these two categories due to the long-term effects that mycoplasma has on eukaryotic cells and the resulting interactions. 11 Mycoplasma infection was verified using at least three of the mycoplasma detection assays indicated above.
Treatment with antibiotics
In most instances, an infected cell line was divided into several aliquots which were then treated in parallel. For some cell lines, aliquots of positive cells were treated at different time points with different antibiotics. Finally, in cases of resistance or culture death, an untreated, cryopreserved aliquot of the originally positive cells was retreated again. It is important to emphasize that prior to any attempt at antibiotic mycoplasma eradication, one or more ampoules with untreated mycoplasma-positive cells should be frozen and stored in liquid nitrogen (of course, properly marked as 'mycoplasmapositive' and, if possible, in separate tanks). In the event of complete resistance of the contaminants to the antibiotics, the same treatment might be repeated or a different regimen might be chosen.
Besides cure and resistance, the third type of possible outcome of the antibiotic treatment is loss of the culture which is presumably caused by cytotoxic effects of the reagents also on the eukaryotic cells. Again, also with regard to that scenario, it is important to store spare mycoplasma-positive cells prior to treatment.
In order to avoid culture loss and mycoplasma resistance, it is of advantage to take the following steps ( Table 3) . As the cells will be under stress, we increase the usually employed FBS concentration and culture the cells at the maximum cell density. Handling of the cells and a close observation of the culture under the inverted microscope is easier in six-or 24-well-culture plates. While we recommend daily treatment (exchange of spent medium with fresh complete medium and addition of antibiotics), occasionally an intermittent break of 1 day in the treatment schedule may be necessary to let the cells recover (particularly during treatment with BM-cyclin). Most mycoplasma-positive LL cell cultures contain clumps of cells. Hence, in order to allow physical access of the antibiotics to the cell surface of all cells (where commonly the mycoplasmas are attached) and to avoid sanctuaries for the infectants, it is important to break up these cell aggregates, for instance by vigorous pipetting. The antibiotics are lightsensitive and degrade. Some regimens require dilutions of the reagents which we prepared freshly as stock solutions each time prior to the start of a treatment cycle. We add the antibiotics directly to the cultures at the appropriate amounts (prior to thorough mixing). Table 3 Steps recommended to avoid culture loss and mycoplasma resistance 
Results of antibiotic treatment
On aggregate, 433 cultures from 123 mycoplasma-positive cell lines were exposed to one of the five different antibiotic regimens. The results are summarized in Figure 1 . Mycoplasma infection was eliminated by the various antibiotics in 71% to 86% of the cultures treated. It is important to emphasize that the decontamination was total and permanent as we did not detect any mycoplasmas in the treated cultures at day +14 of treatment or at later time points (as examined by at least three of the robust mycoplasma detection methods, see Materials and methods). Hence the cell cultures were cured.
The percentages of cultures with mycoplasma infectants resistant to the antibiotics were in the range of 3 to 20%. The third possible outcome of antibiotic treatment, which is the loss of the cell culture, occurred in 3% to 11% of the cases.
Of the 123 mycoplasma-positive LL cell lines, all but five (96%) could be cured in a first round of antibiotic treatment with at least one regimen. The cells of these residual five cell lines died during antibiotic treatment. It is of note that these cell lines had all arrived with a rather low cell viability and poor or no cell growth at all; due to the limited total cell number available, it was not possible to cryopreserve back-up samples for second attempts and it is questionable whether these cultures would have even survived without antibiotic treatment.
In the event of resistance or loss of culture and availability of frozen back-up mycoplasma-positive aliquots, cells were treated again in 27 second attempts with the same reagent. These efforts increased the overall cure rates as follows: BMcyclin, 86% → 93%; enrofloxacin, 83% → 87%; ciprofloxacin, 78% → 82%; MRA, 71% → 77%.
In previous studies we have noted cross-resistance between the various quinolones which could, however, be overcome by BM-cyclin. 10 Hence, once a culture appears to be resistant to a quinolone, a salvage treatment of these quinolone-resistant cells with BM-cyclin may be possible.
Figure 1
Treatment efficiency of anti-mycoplasma antibiotics. The outcomes of 433 treatments of 123 mycoplasma-positive LL cell lines with either BM-cyclin, sparfloxacin, enrofloxacin, ciprofloxacin, or MRA are shown. The results are presented as percentage of cultures that were either cured or that remained mycoplasma-contaminated (due to resistance) or that were lost during the treatment period (due to cytotoxicity). The number of cultures treated in each category is indicated (n).
Leukemia
Discussion
In the perennial fight against mycoplasma, progress was assisted greatly by the availability of specific anti-mycoplasma antibiotics and was expedited by the advent of sensitive and reliable mycoplasma detection methods such as PCR. 8 Obviously, it is important to know the efficacy of these antibiotics for the eradication of mycoplasma in cultures, the practicability of the approach, and the potential side-effects on the eukaryotic cells. To address these issues, the largest currently available collection of human LL cell lines was screened in a prospective manner in order to detect all mycoplasma-positive cultures and to then attempt to cleanse them.
A high treatment efficacy is illustrated by the percentages of successful outcomes: 71% to 86% of the cultures were permanently cleansed of the mycoplasma contaminants using the various antibiotics. With regard to the overall outcome, 96% of the cell lines were rendered mycoplasma-free. The five LL cell lines which could not be cured were lost as all the cells died during treatment. It is not possible to conclude whether these cells died solely as a consequence of drug action (hypersensitivity to the antibiotics) or also as a result of stress induced by the chronic mycoplasma infection (all these cell lines had arrived strongly infected with very low viability, poor cell growth and minimal total cell numbers; back-up cells could not be cryopreserved, precluding any second attempts).
The practicability and simplicity of the approach are obvious because mycoplasma-positive cell lines were cultured essentially under the same conditions during the treatment period as before decontamination.
With regard to side-effects on the eukaryotic cells, four unwanted developments may be considered: (1) strong cytotoxicity leading to cell death via apoptosis; a few precautionary steps might be advantageous to avoid this loss of culture (Table 3) ; (2) with regard to cytostatic effects, a certain degree of mild to pronounced but reversible growth inhibition may occur in most cultures under treatment; (3) loss of special cellular characteristics; and (4) clonal selection of treated cells.
The possibility that the phenotype and genotype of the treated cells are altered due to toxic effects of the antibiotics on the cells or due to selection of subclones with loss of special cellular characteristics has not been addressed here. Such 'collateral damage' would, of course, be of great concern. These possible sequelae can be quite readily examined applying the recently developed gene expression profiling with cDNA microarrays. Such work is in progress. It should be mentioned that the possibly altered phenotype might have been caused by the mycoplasma infection itself.
Treatment failure resulting from the resistance of the mycoplasma cell population appears to be a manifestation of two distinctly different phenomena: (1) the constitutive or acquired metabolic resistance of the mycoplasma cells to antibiotic reagents; and (2) the proliferation of mycoplasma cells which survived antibiotic therapy once the treatment has concluded. We discourage the continuous and routine addition of antimycoplasma antibiotics to the culture medium (which would be similar to the customary, but equally not recommendable routine use of penicillin-streptomycin against other bacteria) because acquired resistance would quickly develop as a result of this chronic drug exposure.
We have summarized our experience in the treatment algorithm presented in Figure 2 . It is important to keep mycoplasma-positive original cells as cryopreserved back-ups. Any Recommended scheme for mycoplasma eradication. An arsenal of different antibiotics can be used to treat mycoplasma-contaminated LL cell lines with a high rate of expected success. We recommend (1) cryopreservation of original mycoplasma-positive cells as back-ups; and (2) splitting of the growing cells into different aliquots (eg in a 24-well plate). These aliquots should be exposed singly to the various antibiotics. It is important to point out that quinoloneresistant cultures could still be cleansed by BM-cyclin. Post-treatment mycoplasma analysis and routine monitoring with a sensitive and reliable method (eg PCR) are of utmost importance.
of the highly effective antibiotic regimens proposed can be used. A strict PCR follow-up is recommended, with the first analysis 2-3 weeks after treatment to document complete mycoplasma eradication and, subsequently, at least once a month during active culturing in order to monitor the mycoplasma status. While we had shown previously that antibiotic treatment can definitely cure the infected cultures, 12 periodical monitoring is nevertheless mandatory as reinfection remains a continuous threat. In case of unsuccessful treatment, second attempts with untreated mycoplasma-positive back-up cells may be tried.
In our extensive experience, eradication of mycoplasma with antibiotic treatment is a time-consuming but worthwhile and efficient approach. More than 90% of the mycoplasmapositive cell lines were effectively cleansed of the contaminants, validating the general utility of this procedure which can be regarded as the technically most simple option, with the most promising results.
